Clinical Trial Update: Marizomib Central Nervous System (CNS) [Phase 2]

View source ↗

Summary

A Phase 2 trial of marizomib for multiple myeloma (including relapsed disease) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Marizomib (marizomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Status: WITHDRAWN